サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：緑内障の世界市場 - 市場シェア・規模・動向・業界分析：薬剤クラス別、流通チャネル別、疾患タイプ別、地域別、セグメント予測（2022年～2030年）
市場調査レポート
商品コード
1150069

緑内障の世界市場 - 市場シェア・規模・動向・業界分析：薬剤クラス別、流通チャネル別、疾患タイプ別、地域別、セグメント予測（2022年～2030年）

Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prostaglandin Analogs, Beta-blockers, Adrenergic Agonists, Carbonic Anhydrase Inhibitors); By Distribution Channel; By Disease Type; By Region; Segment Forecast, 2022-2030
出版日: | 発行: Polaris Market Research | ページ情報: 英文 117 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.36円
緑内障の世界市場 - 市場シェア・規模・動向・業界分析：薬剤クラス別、流通チャネル別、疾患タイプ別、地域別、セグメント予測（2022年～2030年）
出版日: 2022年10月01日
発行: Polaris Market Research
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の緑内障の市場規模は、2030年までに97億7,000万米ドルに達すると予測されています。

当レポートでは、世界の緑内障市場を調査しており、市場の概要、市場規模や予測、動向、促進要因・抑制要因、薬剤クラス別・流通チャネル別・疾患タイプ別・地域別などの分析、さらに企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

  • レポートの説明
    • 調査の目的
    • 市場範囲
    • 前提条件
  • 利害関係者

第2章 エグゼクティブサマリー

  • 市場のハイライト

第3章 調査手法

  • 概要
    • データマイニング
  • 情報源
    • 一次情報
    • 二次情報

第4章 世界の緑内障市場の洞察

  • 緑内障 - 業界のスナップショット
  • 緑内障市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 新規参入者の脅威
    • 買い手の交渉力
    • 代替品の脅威
    • 既存企業間の競争力
  • PESTEL分析
  • 緑内障市場の業界動向
  • バリューチェーン分析
  • COVID-19影響分析

第5章 世界の緑内障市場：薬剤クラス別

  • 主な調査結果
  • イントロダクション
    • 世界の緑内障市場、薬剤クラス別（2018年～2030年）
  • プロスタグランジン類似体
    • 世界の緑内障市場、プロスタグランジン類似体別、地域別（2018年～2030年）
  • ベータ遮断薬
    • 世界の緑内障市場、ベータ遮断薬別、地域別（2018年～2030年）
  • アドレナリン作動薬
    • 世界の緑内障市場、アドレナリン作動薬別、地域別（2018年～2030年）
  • 炭酸脱水酵素阻害剤
    • 世界の緑内障市場、炭酸脱水酵素阻害剤別、地域別（2018年～2030年）
  • その他
    • 世界の緑内障市場、その他別、地域別（2018年～2030年）

第6章 世界の緑内障市場：流通チャネル別

  • 主な調査結果
  • イントロダクション
    • 世界の緑内障市場、流通チャネル別（2018年～2030年）
  • 病院薬局
    • 世界の緑内障市場、病院薬局別、地域別（2018年～2030年）
  • 小売薬局
    • 世界の緑内障市場、小売薬局別、地域別（2018年～2030年）
  • オンライン薬局
    • 世界の緑内障市場、オンライン薬局別、地域別（2018年～2030年）

第7章 世界の緑内障市場：疾患タイプ別

  • 主な調査結果
  • イントロダクション
    • 世界の緑内障市場、疾患タイプ別（2018年～2030年）
  • 開放隅角緑内障
    • 世界の緑内障市場、開放隅角緑内障別、地域別（2018年～2030年）
  • 閉塞隅角緑内障
    • 世界の緑内障市場、閉塞隅角緑内障別、地域別（2018年～2030年）
  • その他
    • 世界の緑内障市場、その他別、地域別（2018年～2030年）

第8章 世界の緑内障市場：地域別

  • 主な調査結果
  • イントロダクション
    • 緑内障市場の評価、地域別（2018年～2030年）
  • 緑内障市場 - 北米
    • 北米：緑内障市場、薬剤クラス別（2018年～2030年）
    • 北米：緑内障市場、疾患タイプ別（2018年～2030年）
    • 北米：緑内障市場、流通チャネル別（2018年～2030年）
    • 緑内障市場 - 米国
    • 緑内障市場 - カナダ
  • 緑内障市場 - 欧州
    • 欧州：緑内障市場、薬剤クラス別（2018年～2030年）
    • 欧州：緑内障市場、疾患タイプ別（2018年～2030年）
    • 欧州：緑内障市場、流通チャネル別（2018年～2030年）
    • 緑内障市場 - 英国
    • 緑内障市場 - フランス
    • 緑内障市場 - ドイツ
    • 緑内障市場 - イタリア
    • 緑内障市場 - スペイン
    • 緑内障市場 - オランダ
    • 緑内障市場 - ロシア
  • 緑内障市場 - アジア太平洋
    • アジア太平洋：緑内障市場、薬剤クラス別（2018年～2030年）
    • アジア太平洋：緑内障市場、疾患タイプ別（2018年～2030年）
    • アジア太平洋：緑内障市場、流通チャネル別（2018年～2030年）
    • 緑内障市場 - 中国
    • 緑内障市場 - インド
    • 緑内障市場 - マレーシア
    • 緑内障市場 - 日本
    • 緑内障市場 - インドネシア
    • 緑内障市場 - 韓国
  • 緑内障市場 - 中東・アフリカ
    • 中東・アフリカ：緑内障市場、薬剤クラス別（2018年～2030年）
    • 中東・アフリカ：緑内障市場、疾患タイプ別（2018年～2030年）
    • 中東・アフリカ：緑内障市場、流通チャネル別（2018年～2030年）
    • 緑内障市場 - サウジアラビア
    • 緑内障市場 - アラブ首長国連邦
    • 緑内障市場 - イスラエル
    • 緑内障市場 - 南アフリカ
  • 緑内障市場 - ラテンアメリカ
    • ラテンアメリカ：緑内障市場、薬剤クラス別（2018年～2030年）
    • ラテンアメリカ：緑内障市場、疾患タイプ別（2018年～2030年）
    • ラテンアメリカ：緑内障市場、流通チャネル別（2018年～2030年）
    • 緑内障市場 - メキシコ
    • 緑内障市場 - ブラジル
    • 緑内障市場 - アルゼンチン

第9章 競合情勢

  • 拡大・買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/協定/公開

第10章 企業プロファイル

  • Allergan PLC
  • Aristo Pharmaceuticals Pvt. Ltd
  • Aerie Pharmaceuticals Company
  • Akorn operating company LLC
  • Bausch & Lomb Incorporated
  • Cipla Incorporation
  • Fera Pharmaceuticals, LLC
  • Inotek Pharmaceuticals
  • Merck KGaA
  • Novartis AG
  • Pfizer Incorporation
  • Santen Pharmaceutical Co., Ltd
  • Teva Pharmaceutical Industries Ltd
  • Valeant Pharmaceuticals International, Inc.
図表

List of Tables

  • Table 1 Global Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 2 Global Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 3 Global Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 4 Glaucoma Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 5 North America: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 6 North America: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 7 North America: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 8 U.S.: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 9 U.S.: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 10 U.S.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 11 Canada: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 12 Canada: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 13 Canada: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 14 Europe: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 15 Europe: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 16 Europe: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 17 UK: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 18 UK: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 19 UK: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 20 France: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 21 France: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 22 France: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 23 Germany: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 24 Germany: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 25 Germany: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 26 Italy: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 27 Italy: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 28 Italy: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 29 Spain: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 30 Spain: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 31 Spain: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 32 Netherlands: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 33 Netherlands: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 34 Netherlands: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 35 Russia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 36 Russia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 37 Russia: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 38 Asia Pacific: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 39 Asia Pacific: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 40 Asia Pacific: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 41 China: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 42 China: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 43 China: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 44 India: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 45 India: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 46 India: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 47 Malaysia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 48 Malaysia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 49 Malaysia: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 50 Japan: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 51 Japan: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 52 Japan: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 53 Indonesia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 54 Indonesia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 55 Indonesia: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 56 South Korea: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 57 South Korea: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 58 South Korea: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 59 Middle East & Africa: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 60 Middle East & Africa: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 61 Middle East & Africa: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 62 Saudi Arabia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 63 Saudi Arabia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 64 Saudi Arabia: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 65 UAE: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 66 UAE: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 67 UAE: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 68 Israel: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 69 Israel: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 70 Israel: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 71 South Africa: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 72 South Africa: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 73 South Africa: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 74 Latin America: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 75 Latin America: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 76 Latin America: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 77 Mexico: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 78 Mexico: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 79 Mexico: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 80 Brazil: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 81 Brazil: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 82 Brazil: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • Table 83 Argentina: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 84 Argentina: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • Table 85 Argentina: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)

List of Figures

Figure 1. Global Glaucoma Market, 2018 - 2030 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Approach

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Distribution Channel

Figure 7. Global Glaucoma Market, by Distribution Channel, 2021 & 2030 (USD Billion)

Figure 8. Market by Drug Class

Figure 9. Global Glaucoma Market, by Drug Class, 2021 & 2030 (USD Billion)

Figure 10. Market by Disease Type

Figure 11. Global Glaucoma Market, by Disease Type, 2021 & 2030 (USD Billion)

Figure 12. Glaucoma Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 13. Strategic Analysis - Glaucoma Market

目次
Product Code: PM1366

The global glaucoma market size is expected to reach USD 9.77 billion by 2030, according to a new study by Polaris Market Research. The report "Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prostaglandin analogs, Beta-blockers, Adrenergic agonists, Carbonic anhydrase inhibitors, and Others); By Distribution Channel; By Disease Type; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of glaucoma across the globe is the key factor bolstering market growth over the forecast period. Glaucoma is gradually becoming more common among the senior population. The elderly population's increased use of technology, such as smartphones and laptops, is contributing to the rise in glaucoma cases. As per the International Agency for the Prevention of Blindness, in the entire world, glaucoma is the third most common cause of blindness and the fourth most prevalent cause of visual loss.

According to estimates, at least 3 million people are currently blind, and 4 million have glaucoma-related mild to severe vision problems. At least 50 percent of glaucoma sufferers are not aware of their condition. 90% of glaucoma cases in some developing nations go undiagnosed.

Further, it also estimated that, in 2018, glaucoma affected 1.9% of Americans over 40 age. According to estimates, there will be 112 million cases of glaucoma by 2040, up from 76 million in 2020. Vision impairment has become a prominent public health issue as the world's population ages.

One billion people worldwide in 2020 have presbyopia or impaired distance vision. This number is projected to rise to 1/8 billion by 2050. In later life (>60 years), common causes of visual impairment, such as cataracts, glaucoma, age-related vision problems, diabetes mellitus, and presbyopia, are increasingly common.

The market for glaucoma is expanding at a remarkable rate, primarily because of the rising elderly population. The risk of glaucoma is most significant in the elderly population, yet it can also afflict people of other ages. People with diabetes and a history of glaucoma in their families are two more high-risk populations. Other market-driving drivers include rising awareness, rising healthcare costs, and screening.

Glaucoma Market Report Highlights

The clinics segment is anticipated to grow at a fastest CAGR over the forecast period. The number of glaucoma cases worldwide has increased, which has increased the demand for ophthalmic clinic treatments. The necessity for ophthalmology clinics in the medical sector has increased as a result of an increase in eye illnesses and technological advancements.

Beta blockers segment accounted for a significant revenue share in 2021. Due to their relative affordability, beta blockers are the most frequently chosen medication by patients. The market is seeing an increase in demand for beta-blocker eye drops due to rising treatment costs.

Asia Pacific is expected to witness fastest growth over the projected period. The market's demand for glaucoma medications has expanded as a result of rising government financing for the medical sector.

The global glaucoma market is highly competitive owing to the existence of large market players with a global presence including Allergan PLC, Bausch & Lomb Incorporated, Cipla Incorporation, Inotek Pharmaceuticals, Merck KGaA, Novartis AG, Pfizer Incorporation, Teva Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International, Inc.

Polaris Market Research has segmented the glaucoma market report based on drug class, distribution channel, disease type, and region:

Glaucoma, Drug Class Outlook (Revenue - USD Billion, 2018 - 2030)

Prostaglandin analogs

Beta-blockers

Adrenergic agonists

Carbonic anhydrase inhibitors

Others

Glaucoma, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital pharmacy

Retail pharmacy

Online Pharmacy

Glaucoma, Disease Type Outlook (Revenue - USD Billion, 2018 - 2030)

Open-angle glaucoma

Angle-closure glaucoma

Others

Glaucoma, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Glaucoma Market Insights

  • 4.1. Glaucoma - Industry Snapshot
  • 4.2. Glaucoma Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence Glaucoma to bolster market growth
      • 4.2.1.2. Increasing product under pipeline and recent product launches to accelerate growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Drug recalls by major players is projected to hinder demand for Glaucoma therapeutics
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Glaucoma Market Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Glaucoma Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 5.3. Prostaglandin Analogs
    • 5.3.1. Global Glaucoma Market, by Prostaglandin Analogs, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Beta-blockers
    • 5.4.1. Global Glaucoma Market, by Beta-blockers, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Adrenergic Agonists
    • 5.5.1. Global Glaucoma Market, by Adrenergic Agonists, by Region, 2018 - 2030 (USD Billion)
  • 5.6. Carbonic Anhydrase Inhibitors
    • 5.6.1. Global Glaucoma Market, by Carbonic Anhydrase Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Other Glaucoma Market, by Region, 2018 - 2030 (USD Billion)

6. Global Glaucoma Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 6.3. Hospital pharmacy
    • 6.3.1. Global Glaucoma Market, by Hospital pharmacy, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Retail pharmacy
    • 6.4.1. Global Glaucoma Market, by Retail pharmacy, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Online Pharmacy
    • 6.5.1. Global Glaucoma Market, by Online Pharmacy, by Region, 2018 - 2030 (USD Billion)

7. Global Glaucoma Market, by Disease Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 7.3. Open-angle
    • 7.3.1. Global Glaucoma Market, by Open-angle, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Angle-closure
    • 7.4.1. Global Glaucoma Market, by Angle-closure, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Other Glaucoma Market, by Region, 2018 - 2030 (USD Billion)

8. Global Glaucoma Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Glaucoma Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 8.3. Glaucoma Market - North America
    • 8.3.1. North America: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.3.2. North America: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.3.3. North America: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.3.4. Glaucoma Market - U.S.
      • 8.3.4.1. U.S.: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.3.4.2. U.S.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.3.4.3. U.S.: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.3.5. Glaucoma Market - Canada
      • 8.3.5.1. Canada: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.3.5.2. Canada.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.3.5.3. Canada: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.4. Glaucoma Market - Europe
    • 8.4.1. Europe: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.2. Europe.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.3. Europe: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.4. Glaucoma Market - UK
      • 8.4.4.1. UK: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.4.2. UK.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.4.3. UK: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.5. Glaucoma Market - France
      • 8.4.5.1. France: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.5.2. France.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.5.3. France: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.6. Glaucoma Market - Germany
      • 8.4.6.1. Germany: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.6.2. Germany.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.6.3. Germany: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.7. Glaucoma Market - Italy
      • 8.4.7.1. Italy: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.7.2. Italy.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.7.3. Italy: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.8. Glaucoma Market - Spain
      • 8.4.8.1. Spain: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.8.2. Spain.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.8.3. Spain: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.9. Glaucoma Market - Netherlands
      • 8.4.9.1. Netherlands: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.9.2. Netherlands.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.9.3. Netherlands: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.10. Glaucoma Market - Russia
      • 8.4.10.1. Russia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.10.2. Russia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.10.3. Russia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.5. Glaucoma Market - Asia Pacific
    • 8.5.1. Asia Pacific: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.5.2. Asia Pacific.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.3. Asia Pacific: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.4. Glaucoma Market - China
      • 8.5.4.1. China: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.4.2. China.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.4.3. China: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.5. Glaucoma Market - India
      • 8.5.5.1. India: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.5.2. India.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.5.3. India: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.6. Glaucoma Market - Malaysia
      • 8.5.6.1. Malaysia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.6.2. Malaysia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.6.3. Malaysia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.7. Glaucoma Market - Japan
      • 8.5.7.1. Japan: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.7.2. Japan.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.7.3. Japan: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.8. Glaucoma Market - Indonesia
      • 8.5.8.1. Indonesia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.8.2. Indonesia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.8.3. Indonesia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.9. Glaucoma Market - South Korea
      • 8.5.9.1. South Korea: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.9.2. South Korea.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.9.3. South Korea: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.6. Glaucoma Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.6.2. Middle East & Africa.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.6.3. Middle East & Africa: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.4. Glaucoma Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.5. Glaucoma Market - UAE
      • 8.6.5.1. UAE: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.5.2. UAE.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.6.5.3. UAE: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.6. Glaucoma Market - Israel
      • 8.6.6.1. Israel: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.6.2. Israel.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.6.6.3. Israel: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.7. Glaucoma Market - South Africa
      • 8.6.7.1. South Africa: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.7.2. South Africa.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.6.7.3. South Africa: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.7. Glaucoma Market - Latin America
    • 8.7.1. Latin America: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.7.2. Latin America.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.7.3. Latin America: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.7.4. Glaucoma Market - Mexico
      • 8.7.4.1. Mexico: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.4.2. Mexico.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.7.4.3. Mexico: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.7.5. Glaucoma Market - Brazil
      • 8.7.5.1. Brazil: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.5.2. Brazil.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.7.5.3. Brazil: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.7.6. Glaucoma Market - Argentina
      • 8.7.6.1. Argentina: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.6.2. Argentina.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.7.6.3. Argentina: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Allergan PLC
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Aristo Pharmaceuticals Pvt. Ltd
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Aerie Pharmaceuticals Company
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Akorn operating company LLC
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bausch & Lomb Incorporated
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Cipla Incorporation
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Fera Pharmaceuticals, LLC
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Inotek Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Merck KGaA
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Novartis AG
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Pfizer Incorporation
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Santen Pharmaceutical Co., Ltd
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Teva Pharmaceutical Industries Ltd
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Valeant Pharmaceuticals International, Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development